This new scientific data from iRhythm builds on the body of clinical evidence – including real-world comparative effectiveness and comparative studies – that continues to highlight the value of iRhythm's Zio products and services. Life-threatening ventricular arrhythmias, especially ventricular tachycardia and ventricular fibrillation, cause about 300,000 deaths each year in the United States and account for nearly half of all deaths from cardiac causes. Early detection and diagnosis are essential to treat these arrhythmias and prevent adverse health outcomes. "These studies thematically demonstrate the value of iRhythm's Zio products and services - particularly in identifying ventricular arrhythmias for risk stratification and disease management," said Extended ambulatory ECG monitoring improves identification of high-risk patients with hypertrophic cardiomyopathy The EXAMINE-HCM study showed that in patients with hypertrophic cardiomyopathy (HCM) -a heart condition that affects 1 in 500 people i Main conclusions: The PVC Load Analysis Study: Premature Ventricular Complexes (PVC): Evaluation of Load Density in a Large National Cohort Population to Better Define the Optimal Duration of ECG Monitoring The PVC Burden Analysis Study of 106,705 patients shows that increased monitoring for at least seven to 10 days in duration is associated with greater accuracy in categorizing patients by level of PVC burden. The results are important, as classification errors can affect clinical decision-making. Main conclusions: The prognostic study of non-sustained VT: practical variation after ambulatory ECG detection of non-sustained ventricular tachycardia in the non-cardiac patient In the Non-Sustained VT Prognosis Study, a retrospective study of Main conclusions: Flec-ARVC Trial: Randomized Placebo-Controlled Trial of Flecainide in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy The Flec-ARVC study, conducted at Main conclusions: About the study "Extended ambulatory ECG monitoring improves identification of high-risk patients with hypertrophic cardiomyopathy" The study authors evaluated 236 patients with hypertrophic cardiomyopathy (HCM) (49 ± 12 years; 72% male) without a primary prevention implantable cardioverter-defibrillator previously assessed as having low or intermediate risk of sudden death (SD) at 14 days of continuous ambulatory monitoring through Zio XT. NSVT episodes were evaluated during the first 48 hours of monitoring and compared with NSVT identified in the subsequent two to 14 days. NSVT episodes with ≥1 of the following criteria were considered higher risk as a marker of DS: ≥ 200 beats per minute, ≥ eight beats, ≥ three runs in a consecutive 48-hour period. Among the 236 patients, 114 (48%) had ≥ one cycle of NSVT, with a median of two cycles (IQR: 1-4) during the entire monitoring period, including 86 patients with ≤ four cycles (36%), 13 with five to nine runs (6%) and 15 with ≥10 runs (7%). The diagnostic yield of NSVT detection was 18% during the first 48 hours of monitoring compared to 48% after 14 days, with 63% of initial NSVT episodes occurring after the first 48 hours (72 of 114). Likewise, the diagnostic yield of detecting high-risk NSVT episodes was 8% during the first 48 hours compared to 24% at 14 days, with 64% of the initial runs of high-risk NSVT occurring after the first 48 hours. hours (36 out of 56). Om undersøgelsen "Premature ventricular complexes: assessing load density in a large national cohort population to better define the optimal duration of ECG monitoring" Patients with a PVC burden ≥5%, age ≥18, and a period of use ≥13 days were analyzed between About the study "Practical variation after ambulatory ECG detection of non-sustained ventricular tachycardia in non-cardiac patients" The authors conducted a retrospective cohort study using data from About the study "Randomized placebo-controlled trial of Flecainide in patients with arrhythmogenic right ventricular cardiomyopathy" The study authors conducted a To learn more about iRhythm, including its portfolio of Zio products and services, visit irhythmtech.com. About Investor Relations Contact: Counted by iRhythm Media: Fonte: iRhythm 2023 GlobeNewswire, Inc., child
Authors:
Authors:
Authors:
Authors:
iRhythm is a leading digital health company that creates trusted solutions that detect, predict and prevent disease. By combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to provide better data, better insights and better health for all.
Stephanie Zhadkevitj
(919) 452-5430
investidores@irhythmtech.com
(310) 528-6306
irhythm@highwirepr.com
New iRhythm Data Reinforces the Utility of Long-Term Ambulatory Cardiac Monitoring for Higher Diagnostic Yield and Improved Diagnostic Accuracy of Actionable Arrhythmias | MarketScreener (2023)
(Video) Webinar: Get Your Service Supply Chain in Rhythm, 21 July 2021
See Also
New iRhythm Data Reinforces Utility of Long-Term Ambulatory Cardiac Monitoring for Higher Diagnostic Yield and Improved Diagnostic Accuracy of Actionable Arrhythmias - iRhythm Technologies (NASDAQ:IRTC)New iRhythm data supports the use of long-term ambulatory cardiac monitoringFlecainide monotherapy is an option for selected patients with β-blockade-intolerant catecholaminergic polymorphic ventricular tachycardiaNew iRhythm data reinforces the usefulness of long-term ambulatory cardiac monitoring to increase diagnostic throughput and improve diagnostic accuracy of actionable arrhythmias - TipRanks.comReferences
- https://balistarling.afphila.com/science/article/pii/S1547527115011972
- https://www.marketscreener.com/quote/stock/IRHYTHM-TECHNOLOGIES-INC-31670646/news/New-Data-From-iRhythm-Reinforce-the-Utility-of-Long-Term-Ambulatory-Cardiac-Monitoring-for-Increased-43912493/
- https://www.massdevice.com/data-irhythm-long-term-ambulatory-cardiac-monitoring/
- https://www.benzinga.com/pressreleases/23/05/g32506469/new-data-from-irhythm-reinforce-the-utility-of-long-term-ambulatory-cardiac-monitoring-for-increas
- https://www.tipranks.com/news/press-releases/new-data-from-irhythm-reinforce-the-utility-of-long-term-ambulatory-cardiac-monitoring-for-increased-diagnostic-yield-and-improved-diagnostic-accuracy-of-actionable-arrhythmias
Top Articles
The amygdala, the brain's threat detector, plays an important role in autism
VA Disability Assessments for Hip Pain and Hip Disorders | CCK law
Venlafaxine |
apotheek dienst
VA Classification for Bilateral Knee Injuries and Conditions - Berry Law
Lợi ích của isoflavone đối với sức khỏe nội tiết của phụ nữ
24 Erstaunliche Informationen zu Wann Wasserwechsel In Der Einlaufphase? - Alles über Aquarien und mehr
25 Wichtige Hinweise zu Wie Lange Dauert Die Einlaufphase Im Aquarium? - Alles über Aquarien und mehr
Latest Posts
Seizure That Causes Body To Go Limp
Significant Damage To Which Of The Following Parts Of The Brain Will Most Likely Cause A Person To Fall Into A Deep Coma From Which The Person Will Be Unable To Awaken?
What Is The Main Idea Of Levels Of Processing Theory?
How Many Children Under 16 Have Epilepsy
Why Is There A Lump In My Earlobe
Article information
Author: Terrell Hackett
Last Updated: 27/08/2023
Views: 6053
Rating: 4.1 / 5 (52 voted)
Reviews: 91% of readers found this page helpful
Author information
Name: Terrell Hackett
Birthday: 1992-03-17
Address: Suite 453 459 Gibson Squares, East Adriane, AK 71925-5692
Phone: +21811810803470
Job: Chief Representative
Hobby: Board games, Rock climbing, Ghost hunting, Origami, Kabaddi, Mushroom hunting, Gaming
Introduction: My name is Terrell Hackett, I am a gleaming, brainy, courageous, helpful, healthy, cooperative, graceful person who loves writing and wants to share my knowledge and understanding with you.